Eikon Therapeutics, Inc. (EIKN)
7.26
-0.98
(-11.89%)
USD |
NASDAQ |
Oct 23, 16:00
7.24
-0.02
(-0.28%)
After-Hours: 20:00
Eikon Therapeutics Debt to Equity Ratio : 0.5407 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.5407 |
| March 31, 2026 | 0.4628 |
| December 31, 2025 | 0.9111 |
| Date | Value |
|---|---|
| June 30, 2025 | |
| March 31, 2025 | |
| December 31, 2024 | 0.8568 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 779.57M |
| Total Liabilities (Quarterly) | 313.07M |
| Shareholders Equity (Quarterly) | 466.50M |
| Current Ratio | 9.892 |
| Net Debt Paydown Yield | -1.41% |